CNR2 and osteoporosis: Therapeutically, PTH1R agonists (teriparatide, abaloparatide) are first-line treatments for osteoporosis, while Cannabinoid receptor 2 (CNR2/CB2) agonists show promise in preventing ovariectomy-induced bone loss by stimulating osteogenesis 55, 56.